Japan's net foreign investment in Japanese stocks in the week of December 6 was 482.3 billion yen, with the previous value of-607.7 billion yen. Japan's net foreign investment in Japanese bonds in the week of December 6 was 1,006.4 billion yen, with the previous value of 176.1 billion yen. Japan bought a net foreign bond of-640.8 billion yen in the week of December 6, with the previous value of 922.4 billion yen. In the week of December 6th, Japan bought foreign stocks net-954.8 billion yen, with the previous value of-544.7 billion yen.Hong Kong suspended the import of poultry meat and poultry products from Ehime Prefecture, Japan. On December 11th, the Center for Food Safety of the Food and Environmental Hygiene Department of Hong Kong announced that in response to the notification from the Ministry of Agriculture, Forestry and Fisheries of Japan that highly pathogenic H5 avian influenza broke out in Ehime Prefecture, Japan, the Center immediately instructed the industry to suspend the import of poultry meat and poultry products (including eggs) from this area to protect public health in Hong Kong. A spokesman for the Centre said that according to the information of the Census and Statistics Department, Hong Kong imported about 2,000 metric tons of frozen poultry meat and 227.42 million eggs from Japan in the first nine months of this year. The spokesman said: "The Center has contacted the Japanese authorities on the incident and will continue to pay close attention to the news of the outbreak of avian influenza issued by the World Organization for Animal Health and relevant authorities, and take appropriate actions in response to the development of the local epidemic."Spot platinum just broke through the $940.00/oz mark, and the latest price was $940.90/oz, up 0.58% in the day; The main force of Nymex platinum futures recently reported $951.9 per ounce, up 0.12% in the day.
Citic Jiantou: We are optimistic about the investment opportunities in the pharmaceutical industry in 2025, focusing on the opportunities of new increase and industry integration. Citic Jiantou Securities reported on December 11th that looking forward to 2025, the reform policy in the pharmaceutical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations on the whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.South Korean President Yin Xiyue: The opposition party tried to paralyze the government. The opposition tried to get me out of office.Warnick, chief financial officer of Robinhood, reduced his holdings of $6.02 million shares, and Jason Warnick, chief financial officer of Robinhood Markets Inc, reported an insider stock transaction to the US Securities and Exchange Commission, reducing his holdings of $6.02 million shares. Robinhood's share price has risen by 15% in the past month.
Huatai Securities: It is expected that the Fed will cut interest rates by 25bp in December, but the path of interest rate cut in 2025 is highly uncertain. Huatai Securities said that the overall inflation in November in the United States was in line with expectations, and the slight cooling of service inflation partially eased the market's concerns about inflation rebound. It is expected that the Fed will cut interest rates by 25bp in December, but the path of interest rate cut in 2025 is highly uncertain. Recently, the overall economic momentum of the United States has rebounded: from September to November, the PMI of Markit manufacturing in the United States has rebounded for three consecutive months; After the election, enterprises, especially small enterprises, are expected to improve, and the recent NFIB SME confidence index has rebounded significantly; The latest Atlanta GDP Now shows that the fourth quarter GDP growth rate of the United States is 3.3% year-on-year. However, considering that the unemployment rate data rebounded in November, and the recent inflation is still relatively moderate, we expect that the recent data may not prevent the Fed from cutting interest rates at its December meeting next week. However, in 2025, the growth and inflation path of the United States was disturbed by the Trump policy, and the Federal Reserve may "make a camera choice" on the basis of watching the overall economic trend. There is uncertainty in the path of interest rate cut in 2025.Zhong Xuegao's subsidiary was forced to execute 16.62 million yuan. According to the legal litigation information, recently, Zhongmao (Shanghai) Food Technology Co., Ltd. added a piece of information about the person to be executed, with the execution target of 16.62 million yuan. The enforcement court is the Yangpu District People's Court in Shanghai. Zhongmao (Shanghai) Food Technology Co., Ltd. was established in June 2020. The legal representative is Wang Keqin, with a registered capital of RMB 10 million, and it is wholly owned by Zhong Xuegao Food (Shanghai) Co., Ltd. Tianyan risk information shows that the company has more than 20 pieces of information about executed persons, and the total amount of execution exceeds 31.62 million yuan. In addition, there are also a number of consumption restriction orders, untrustworthy executed persons (Lao Lai) and final case information.Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide